Alumis (ALMS) Total Current Liabilities (2023 - 2026)
Alumis (ALMS) posted quarterly Total Current Liabilities of $73.3 million for Q4 2025, up 44.01% year-over-year from $50.9 million in Q4 2024, and up 12.08% quarter-over-quarter from $65.4 million in Q3 2025.
Alumis (ALMS) Total Current Liabilities (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Total Current Liabilities for 3 consecutive years, with $73.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 44.01% year-over-year to $73.3 million; the TTM figure through Dec 2025 stood at $73.3 million (up 44.01% YoY), while the FY2025 annual figure was $73.3 million, up 44.01% from the prior year.
- Total Current Liabilities climbed to $73.3 million in Q4 2025 per ALMS's latest filing, from $65.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $85.6 million in Q2 2025 and bottomed at $20.9 million in Q4 2023.
- Historically, Total Current Liabilities has averaged $52.9 million across 3 years, with a median of $55.7 million in 2024.
- On a YoY basis, Total Current Liabilities climbed as much as 156.11% in 2025 and fell as far as 44.01% in 2025.
- Alumis' Total Current Liabilities stood at $20.9 million in 2023, then soared by 143.93% to $50.9 million in 2024, then surged by 44.01% to $73.3 million in 2025.
- Business Quant data shows ALMS's Total Current Liabilities at $73.3 million in Q4 2025, $65.4 million in Q3 2025, and $85.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | 76.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.23 Mn |
| Dec 31, 2025 | 73.32 Mn |
| Sep 30, 2025 | 65.42 Mn |
| Jun 30, 2025 | 85.58 Mn |
| Mar 31, 2025 | 60.45 Mn |
| Dec 31, 2024 | 50.91 Mn |
| Sep 30, 2024 | 33.52 Mn |
| Jun 30, 2024 | 33.41 Mn |
| Dec 31, 2023 | 20.87 Mn |